MetaCap

QuidelOrtho (QDEL) vs Trinity Biotech (TRIB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

QuidelOrtho is the larger company by market cap ($570.9 million vs $5.1 million), about 112.5 times the size, while Trinity Biotech is growing revenue faster (+8.3% vs -1.9%). QuidelOrtho converts more of its revenue into profit, with a net margin of -41.5% versus -51.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

QDEL-32.41%TRIB-7.56%
+24%-6%-35%
Oct 7, 20261 yearNov 20, 2026
QDEL-38.00%TRIB-8.97%
+20%-10%-41%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

QDEL versus TRIB key metrics
MetricQDELTRIB
Share price$8.32$6.24
Market cap$570.86M$5.07M
1-day change-6.73%+13.76%
YTD return-70.87%—
1-year return-65.83%—
5-year return-94.25%—
Forward P/E6.32—
EPS (TTM)$-5.39$-60.00
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$2.73B$61.55M
Revenue growth (YoY)-1.89%+8.31%
Net income (latest FY)$-1.13B$-31.79M
Gross margin46.67%34.83%
Operating margin-33.67%-34.38%
Net margin-41.45%-51.64%
52-week high$35.58$52.50
52-week low$8.06$4.54
Distance from 52-week high-76.62%-88.11%
Analyst consensushold—
Avg. price target upside+80.29%—
Average volume2.04M13.54K
Shares outstanding68.61M813.13K
Employees6,500287
SectorHealth CareHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic SubstancesBiotechnology: In Vitro & In Vivo Diagnostic Substances

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • QuidelOrtho is about 112.5 times larger than Trinity Biotech by market value ($570.86M vs $5.07M).
  • QuidelOrtho is more profitable, keeping -41.5 cents of every revenue dollar as net income versus -51.6 cents for Trinity Biotech.
  • Trinity Biotech grew revenue faster in its latest fiscal year (+8.31% vs -1.89%).

About QuidelOrtho

QDEL stock →

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 6,500 employees

About Trinity Biotech

TRIB stock →

Trinity Biotech plc, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases, such as syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 287 employees

QDEL vs TRIB FAQ

Which is bigger, QuidelOrtho or Trinity Biotech?

QuidelOrtho (QDEL) is larger, with a market capitalization of $570.86M compared with $5.07M for Trinity Biotech (TRIB).

Are QuidelOrtho and Trinity Biotech in the same industry?

Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.

More comparisons